GI-4000 and GI-6207 vaccines are used to target mutated versions of the Ras oncoprotein and CEA expressing tumors respectively.
In the first study, GI-4000, a series of Tarmogen products engineered to express the seven most common KRAS mutations, was administered as a first line therapy to patients with stage I-III non-small cell lung cancer (NSCLC) having a matching KRAS mutation in their tumor.
GI-6207 is a Tarmogen designed to elicit a T cell immune response in patients against cancers that express carcinoembryonic antigen (CEA).
The primary endpoints of the trials were safety and immunogenicity.
GlobeImmune CMO David Apelian said based on these data, they are designing Phase 2 studies to specifically develop these products for a variety of different clinical indications.